Table A1.

Characteristics of Patients With RCC and Melanoma

Patient	Response	Histology	Stage	Anemia (g/dL)	Thrombocytosis (109/L)	Neutrophilia (109/L)	ECOG PS of 2 (Karnofsky score < 80)	Hypercalcemia (mg/dL)	Time From Original Diagnosis to Start of Systemic Therapy (years)	IMDC			Prior Immune Therapy			Prior Therapies (No.)
										Favorable	Intermediate	Poor	IL-2	Anti–CTLA-4	Anti–PD-1
RCC (AM0010 20 μg/kg)
1	SD	Clear cell	IV	8.6	332	7.76	1	10.56	0.18			X	X			3
2	PR	Clear cell	IV	12.6	160	2.1	0	10.22	10.12		X		X			6
3	PR	Clear cell	IV	12.9	286	3.3	0	9.64	3.74		X					2
4	ND	Clear cell	IV	10.2	447	4.1	1	11.34	0.71			X				1
5	SD	Clear cell	IV	18.5	221	3.2	0	9.32	0.12			X				4
6	PD	Translocation	IV	13.3	224	3.73	0	9.96	3.07	X						4
7	PD	Clear cell	IV	10.0	356	6.70	1	10.72	0.19			X				4
8	PD	Clear cell	IV	13.1	231	3.55	0	9.98	0.11		X					3
9	SD	RCC	IV	11.5	726	8.21	1	9.16	0.22			X			X	3
10	PD	Clear cell	IV	12.5	291	4.94	1	9.88	1.63		X					1
11	SD	Chromophobe	IV	11.2	304	3.48	0	9.7	4.18		X					2
12	ND	Medullary carcinoma	IV	10.9	272	3.52	1	9.38	0.36		X					2
13	PR	Clear cell	IV	11.2	241	4.24	1	9.36	3.66		X		X			7
14	ND	Clear cell	IV	9.5	410	5.22	0	11.44	9.55		X			X		3
15	SD	Clear cell	IV	10.3	474	5.45	0	10.42	0.65			X			X	3
16	PR	Clear cell	IV	13.1	281	5.4	1	9.18	0.09		X					2
17	PD	Clear cell	IV	9.0	142	3.3	1	8.92	0.06		X					3
18	SD	NA	IV	13.7	297	5.9	1	10.42	NA		X					0
19	ND	Clear cell	IV	12.0	237	6.33	0	10.78	2.19		X					7
Melanoma (AM0010 20 or 40 μg/kg)
1	PR	MM, choroidal	IV	LDH normal			1							X		3
2	SD (MXR)	MM, cutaneous	IV	LDH elevated			1							X		1

Abbreviations: CTLA-4, cytotoxic T-cell lymphocyte-4; ECOG PS, Eastern Cooperative Oncology Group performance status; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; LDH, lactate dehydrogenase; MM, metastatic melanoma; MXR, mixed response; NA, not available; ND, not determined; PD, progressive disease; PD-1, programmed death-1; PR, partial response; RCC, renal cell cancer; SD, stable disease